Amplification of the MYC transcription factor family member MYCN drives a range of solid tumours including medulloblastoma, rhabdomyosarcoma, osteosarcoma, Wilms tumour, small cell lung cancer and retinoblastoma, with MYCN overexpression associated with poorer prognoses (Rickman Schulte and Eilers, 2018). This evidence concerns the gene MYC and osteosarcoma.